News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy
Photo: The Lancet Haematology/Twitter
May 18, 2023, 14:56

Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy

NEW: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of PFS in older patients with B-cell ALL: results of a phase 2 trial

Source: The Lancet Haematology/Twitter

blinatumomab Inotuzumab ozogamicin phase 2 trial The Lancet Haematolog
Special Coverage
Science
Feb 9, 2025, 18:36
Rennie Qin: A cross-sectional study of essential surgical, obstetric, and anaesthesia care capacity in Fiji
Insight
Feb 9, 2025, 18:33
Jennifer Lovick: The latest research from technology in cancer research and treatment's January round-up
Blog
Feb 9, 2025, 18:29
Don S. Dizon: Championing the ideals is essential and valued
Blog
Feb 9, 2025, 18:21
The recent progress in treating small cell lung cancer
Blog
Feb 9, 2025, 18:09
Sarah Louden: 10th Annual West Oncology Conference
Blog
Feb 9, 2025, 18:06
Luis Raez: Our lung cancer faculty at 2025 PRIMO Meeting in Hawaii
Blog
Feb 9, 2025, 17:59
Melinda Bachini: Honored to attend the Johns Hopkins Medicine Updates GI Cancers
Blog
Feb 9, 2025, 17:54
David Steensma: Lentiviral vectors construct integration into TP53
Blog
Feb 9, 2025, 17:38
Roupen Odabashian: Building a HealthTech Company That Transforms Prostate Cancer Care
Blog
Feb 9, 2025, 17:24
Richard Scolyer: My recent scans show some new changes
Blog
Feb 9, 2025, 17:22
Paolo A. Ascierto: From melanoma to kidney cancer, vaccine research is making significant strides
Blog
Feb 9, 2025, 17:14
John Barnard: Overhead is a real cost for research institutes